AstraZeneca PLC (NASDAQ:AZN) Given Average Recommendation of “Buy” by Brokerages

AstraZeneca PLC (NASDAQ:AZN) has earned an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $89.75.

A number of equities research analysts recently weighed in on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th.

Institutional Trading of AstraZeneca

Several large investors have recently bought and sold shares of the stock. Stratos Wealth Advisors LLC raised its stake in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares during the last quarter. Bruce G. Allen Investments LLC raised its holdings in shares of AstraZeneca by 19.1% during the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after acquiring an additional 138 shares during the last quarter. Carnegie Investment Counsel lifted its position in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. Crumly & Associates Inc. boosted its stake in shares of AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 3.7 %

Shares of NASDAQ AZN opened at $63.85 on Thursday. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68. The stock’s fifty day simple moving average is $78.45 and its two-hundred day simple moving average is $78.75. The stock has a market capitalization of $197.97 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.